TransCode Therapeutics (RNAZ) Institutional Ownership → A Wave of Creative Destruction Set to Strike June 30 (From Banyan Hill Publishing) (Ad) Free RNAZ Stock Alerts $1.34 +0.22 (+19.64%) (As of 06/6/2024 ET) Add Compare Share Share OwnershipStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Institutional Ownership Changes (13F Filings) for TransCode Therapeutics (NASDAQ:RNAZ)Number ofInstitutional Buyers(last 12 months)2TotalInstitutional Inflows(last 12 months)$1.28MNumber ofInstitutional Sellers(last 12 months)0 Get RNAZ Insider Trade Alerts Want to know when executives and insiders are buying or selling TransCode Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data RNAZ Institutional Buying and Selling by Quarter Ad Banyan Hill PublishingA Wave of Creative Destruction Set to Strike June 30You have until June 30 … then all hell will begin to break loose… The White House and Goldman Sachs predict generative AI will soon replace up to 300 MILLION jobs — one in every four careers … worldwide.Click here for details. TransCode Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails5/20/2024 Virtu Financial LLC55,329$37K0.0%N/A0.836% 11/15/2023 Sabby Management LLC250,309$126K0.1%+32.8%12.330% 4/21/2022 K.J. Harrison & Partners Inc19,987$58K0.0%+24.9%0.155% 2/4/2022 Redmond Asset Management LLC88,010$224K0.1%N/A0.682% 1/26/2022 K.J. Harrison & Partners Inc16,000$41K0.0%N/A0.124% 11/16/2021ACT Capital L.L.C.50,000$150K0.1%N/A0.387% 11/16/2021 National Asset Management Inc.25,000$75K0.0%N/A0.194% 11/16/2021 Two Sigma Securities LLC33,314$100K0.0%N/A0.258% 11/12/2021 AIGH Capital Management LLC1,270,500$3.80M0.8%N/A9.845% (Data available from 1/1/2016 forward) RNAZ Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of RNAZ shares? During the previous two years, the following institutional investors and hedge funds held shares of TransCode Therapeutics shares: Sabby Management LLC ($126K), Virtu Financial LLC ($37K).Learn more on RNAZ's institutional investors. Which institutional investors have been buying TransCode Therapeutics stock? The following institutional investors have purchased TransCode Therapeutics stock in the last 24 months: Sabby Management LLC ($61.87K), and Virtu Financial LLC ($55.33K). How much institutional buying is happening at TransCode Therapeutics? Institutional investors have bought a total of 117,201 shares in the last 24 months. This purchase volume represents approximately $1.28M in transactions. Related Companies: Eagle Pharmaceuticals Institutional Ownership CASI Pharmaceuticals Institutional Ownership Aadi Bioscience Institutional Ownership Kronos Bio Institutional Ownership Lexaria Bioscience Institutional Ownership Clene Institutional Ownership Gain Therapeutics Institutional Ownership Ocuphire Pharma Institutional Ownership Immuneering Institutional Ownership NextCure Institutional Ownership This page (NASDAQ:RNAZ) was last updated on 6/7/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the ...Crypto 101 Media | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | SponsoredCollapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!The FEDNOW Biden Dollar ends cash in a matter of WEEKS Stumbling Biden's dollar next phases begins Oct 21st...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TransCode Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TransCode Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.